1. Activation of the PPARγ/NF-κB pathway by A-MPDA@Fe3O4@PVP via scavenging reactive oxygen species to alleviate hepatic ischemia-reperfusion injury.
- Author
-
Mo, Dong, Cui, Wei, Chen, Linxin, Meng, Juanjuan, Sun, Yuting, Cai, Kaiyong, Zhang, Jixi, Zhang, Jianrong, Wang, Kui, and Luo, Xiaohe
- Abstract
Hepatic ischemia-reperfusion injury (IRI) is a common pathological process during hepatectomy and liver transplantation and the two primary reasons for hepatic IRI are reactive oxygen species (ROS)-mediated oxidative stress and excessive inflammatory responses. Herein, a novel antioxidant nanodrug (A-MPDA@Fe
3 O4 @PVP) is prepared by employing L -arginine-doped mesoporous polydopamine (A-MPDA) nanoparticles as the carrier for deposition of ultra-small ferric oxide (Fe3 O4 ) nanoparticles and further surface modification with polyvinylpyrrolidone (PVP). A-MPDA@Fe3 O4 @PVP not only effectively reduces the aggregation of ultra-small Fe3 O4 , but also simultaneously replicates the catalytic activity of catalase (CAT) and superoxide dismutase (SOD). A-MPDA@Fe3 O4 @PVP with good antioxidant activity can rapidly remove various toxic reactive oxygen species (ROS) and effectively regulate macrophage polarization in vitro. In the treatment of hepatic IRI, A-MPDA@Fe3 O4 @PVP effectively alleviates ROS-induced oxidative stress, reduces the expression of inflammatory factors, and prevents apoptosis of hepatocytes through immune regulation. A-MPDA@Fe3 O4 @PVP can further protect liver tissue by activating the PPARγ/NF-κB pathway. This multiplex antioxidant enzyme therapy can provide new references for the treatment of IRI in organ transplantation and other ROS-related injuries such as fibrosis, cirrhosis, and bacterial and hepatic viral infection. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF